This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Inhaled sevoflurane may promote progression of amnestic mild cognitive impairment: a prospective, randomized parallel-group study

Authors

Liu, Yongzhe, Pan, Ningling, Ma, Yaqun, Zhang, Shengshuo, Guo, Wenzhi, Li, Haihong, Zhou, Jingli, Liu, Gang, Gao, Minglong

Journal

The American Journal Of The Medical Sciences, Volume: 345, No.: 5, Pages.: 355-360

Year of Publication

2013

Abstract

Background: Amnestic mild cognitive impairment (aMCI) is thought to be a transitional stage between normal aging and the development of Alzheimer’s disease (AD). Recent studies have suggested that the inhalational anesthetic isoflurane can induce caspase activation and apoptosis, increase aggregates of β-amyloid (Aβ) levels, and enhance Aβ aggregation. The aim of this study was to investigate whether previous exposure to different anesthetics induced progression of aMCI.; Methods: A prospective, randomized parallel-group study was completed with 180 patients with aMCI who were randomly assigned to a sevoflurane, propofol or lidocaine epidural anesthesia group (n = 60 per group) during an L3 to L4 or an L4 to L5 spinal surgery. Sixty additional outpatients with aMCI served as a control group. Before surgery, all subjects underwent a neuropsychological assessment. Cerebrospinal fluid (CSF) was obtained by lumbar puncture, and neuropsychological assessments were completed in the clinic. CSF Aβ42, total tau and phosphorylated tau181 were quantitatively assayed. The neuropsychological assessments were repeated after 2 years.; Results: Two years after anesthesia, the number of AD cases that emerged did not differ significantly between the groups. However, the number of cases of progressive MCI was greater in the sevoflurane group than in the control group. Age correlated linearly with aMCI progression, whereas sex did not. Both patients with AD and progressive MCI had decreased CSF Aβ42, increased total tau and increased phosphorylated tau levels compared with those with stable MCI and the controls.; Conclusions: Inhaled sevoflurane accelerated the progression of aMCI to progressive MCI in this selected Chinese population.;

Bibtex Citation

@article{Liu_2013, doi = {10.1097/maj.0b013e31825a674d}, url = {http://dx.doi.org/10.1097/MAJ.0b013e31825a674d}, year = 2013, month = {may}, publisher = {Elsevier {BV}}, volume = {345}, number = {5}, pages = {355--360}, author = {Yongzhe Liu and Ningling Pan and Yaqun Ma and Shengshuo Zhang and Wenzhi Guo and Haihong Li and Jingli Zhou and Gang Liu and Minglong Gao}, title = {Inhaled Sevoflurane May Promote Progression of Amnestic Mild Cognitive Impairment: A Prospective, Randomized Parallel-Group Study}, journal = {The American Journal of the Medical Sciences} }

Keywords

ad, administration & dosage, administration inhalation, adverse effects, aged, amnesia, anaesthetics, biological markers, cases, cerebrospinal fluid, chemically induced, diagnosis, different, disease progression, exposure, female, humans, incidence, male, methyl ethers, mild cognitive impairment, neuropsychological tests, of, peptide fragments, prospective studies, to, types

Countries of Study

China

Types of Dementia

Mild Cognitive Impairment (MCI)

Types of Study

Randomised Controlled Trial

Type of Outcomes

Cognition

Settings

Hospital Inpatient Care

Type of Interventions

Risk Factor Modification

Risk Factor Modifications

At risk population